| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.08 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.053 | 0.08 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.095 | 0.08 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.08 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.072 | 0.08 |